BIO.DE लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 21:06):

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments...

Stats
आज की मात्रा	100.00
औसत मात्रा	150.00
बाजार मूल्य	1.41B
EPS	€0 ( 2024-03-28 )
अगली कमाई की तारीख	( €0 ) 2024-05-06
Last Dividend	€0.0400 ( 2019-05-08 )
Next Dividend	€0 ( N/A )
P/E	13.02
ATR14	€0 (0.00%)

Biotest AG सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Biotest AG वित्तीय

Annual	2023
राजस्व:	€684.60M
सकल लाभ:	€271.90M (39.72 %)
EPS:	€3.21

FY	2023
राजस्व:	€684.60M
सकल लाभ:	€271.90M (39.72 %)
EPS:	€3.21

FY	2022
राजस्व:	€516.10M
सकल लाभ:	€124.90M (24.20 %)
EPS:	€-0.800

FY	2021
राजस्व:	€515.60M
सकल लाभ:	€80.70M (15.65 %)
EPS:	€-1.610

Financial Reports:

No articles found.

Biotest AG Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Biotest AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 7.59 - good (75.92%) | Divividend Growth Potential Score: 1.201 - No dividend growth expected in the near future

Information

First Dividend	€0.0667	2000-07-17
Last Dividend	€0.0400	2019-05-08
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	18	--
Total Paid Out	€1.683	--
Avg. Dividend % Per Year	0.00%	--
Score	2	--
Div. Sustainability Score	7.59
Div.Growth Potential Score	1.201
Div. Directional Score	4.40	--

Next Divdend (Est)
(2024-12-30)

€0 Estimate 0.00 %

Dividend Stability

0.04 Very Bad

Dividend Score

2.00

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
FRE.DE	Ex Dividend Junior	2023-05-18	Annually	0.00%
PTTG.F	Ex Dividend Knight	2023-08-15	Semi-Annually	0.00%
ARRD.DE	Ex Dividend Junior	2023-11-13	Sporadic	0.00%
HYI.F	No Dividend Player	2023-06-19	Annually	0.00%
SWF.DE	Ex Dividend Junior	2023-09-01	Quarterly	0.00%
CE2.DE	Ex Dividend Junior	2023-07-12	Annually	0.00%
LEI.DE	Ex Dividend Junior	2023-06-08	Annually	0.00%
VH2.F	Ex Dividend Junior	2023-06-02	Annually	0.00%
DWD.DE	Ex Dividend Junior	2023-07-28	Quarterly	0.00%
NOEJ.DE	Ex Dividend Junior	2023-05-12	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.217	1.500	5.65	8.48	[0 - 0.5]
returnOnAssetsTTM	0.107	1.200	6.43	7.71	[0 - 0.3]
returnOnEquityTTM	0.368	1.500	7.02	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.963	0.800	5.18	4.15	[1 - 3]
quickRatioTTM	0.845	0.800	9.74	7.79	[0.8 - 2.5]
cashRatioTTM	0.308	1.500	9.40	10.00	[0.2 - 2]
debtRatioTTM	0.441	-1.500	2.64	-3.97	[0 - 0.6]
interestCoverageTTM	4.47	1.000	9.46	9.46	[3 - 30]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
freeCashFlowPerShareTTM	-0.884	2.00	-0.442	-0.884	[0 - 20]
debtEquityRatioTTM	1.278	-1.500	4.89	-7.33	[0 - 2.5]
grossProfitMarginTTM	0.432	1.000	6.13	6.13	[0.2 - 0.8]
operatingProfitMarginTTM	0.251	1.000	6.98	6.98	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.00251	1.000	-1.125	-1.125	[0.2 - 2]
assetTurnoverTTM	0.493	0.800	-0.0455	-0.0364	[0.5 - 2]
Total Score				7.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.69	1.000	9.02	0	[1 - 100]
returnOnEquityTTM	0.368	2.50	8.09	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.884	2.00	-0.295	-0.884	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.0404	2.00	-0.0135	-0.0270	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.116	1.500	-2.56	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.00225	1.000	-2.56	0	[0.1 - 0.5]
Total Score				1.201

Biotest AG

Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.

के लिए वास्तविक समय के अद्यतन Biotest AG [BIO.DE]

Upcoming Earnings Alert

Biotest AG Dividend Information - Ex Dividend Junior

Dividend Commentary

Top 10 dividend Companies for XETRA

Dividend Sustainability Score (DSS)

Dividend Growth Score (DGS)